

The European Medicines Agency (EMA) approves extension of shelf life for Strangvac®, a vaccine against equine strangles, to 33 months

Stockholm, May 17th, 2023 - The European Medicines Agency (EMA) has, after reviewing stability data, approved the extension of the shelf life for Strangvac®, to 33 months from previously 24 months.

The Veterinary Medicines Directorate (VMD) the authority responsible for veterinary medicines in the UK, has previously approved the extension of the shelf life for Strangvac®.

"It is positive that the European Medicines Agency (EMA) now has approved a 33-month shelf life for Strangvac®. It provides us with increased flexibility in the logistics chain and facilitates planning of production", comments Andreas Andersson, CEO of Intervacc.

For more information please contact:

Andreas Andersson, CEO

Phone: +46-8-120 10 601, cell +46-73-335 99 70

E-mail: andreas.andersson@intervacc.com

The information was submitted for publication, through the agency of the contact person set out above on May 17, 2023, 15.10 CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company's research and development work. The technology platform is based on fusion proteins produced using recombinant DNA technology. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

About equine strangles

Equine strangles is a severe, common, and highly contagious horse disease where the horse develops fever, nasal discharge, cough, and sometimes large abscesses in the lymph nodes of the head and neck. Equine strangles is caused by the streptococcus bacteria *Streptococcus equi*. The onset of the disease can range from mild cold-like symptoms to severe abscesses in the throat that can burst, leading to breathing difficulties. The mortality rate is up to 10 percent in infected herds, but more typically around 2 percent. Equine strangles can also cause secondary infections such as pneumonia or abscesses in other parts of the body. It affects horses worldwide, except for Iceland where the import of horses is prohibited. Some of the horses that recover from strangles remain persistently infected. These silent carriers are perceived by others as completely healthy animals, but they spread the bacteria to the environment and to other horses with which they come into contact. Outbreaks of equine strangles often have significant consequences for horse owners, as isolation, closure, and other measures are required. The Swedish National Veterinary Institute (SVA) recommends isolating all horses on the premises, both sick and asymptomatic, for four to six weeks from the day of the last symptoms observed in the last affected horse.

About Strangvac®

Strangvac® is approved for sale and marketing in the EU as well as the UK and Norway. Strangvac® has been launched in Sweden, Denmark, the UK, France, Germany, the Benelux region, Austria, Ireland, Poland and Italy. Strangvac® is administered intramuscularly and does not contain any live or attenuated *S. equi* bacteria or *S. equi* DNA. Strangvac® does not contain any of the antigens used in serological tests for equine strangles and therefore does not yield positive results in these tests. This means that vaccinated horses can be distinguished from those who have or have had the infection.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10